Biogen Slides as Newly Disclosed Charges Pressure Near-Term Earnings

Biogen (BIIB) is down 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a fresh regulatory filing that pointed to meaningful acquired in-process research and development, upfront, and milestone charges in the second and third quarters of 2026, which could weigh on near-term earnings per share. Sentiment may also be softer because investors are waiting for updated guidance later this month and are balancing that earnings pressure against Biogen’s recent dealmaking and pipeline expansion.

Details:

Biogen said in a July 1 filing that second-quarter 2026 results are expected to include about $164 million of acquired in-process research and development, upfront, and milestone expense, with an estimated per-share impact of roughly $0.95.

The same filing said third-quarter 2026 results could include another $290 million to $320 million of similar expense, implying an estimated per-share impact of about $1.75 to $1.95.

Biogen previously said updated financial guidance tied to its Apellis acquisition would be provided with its second-quarter report, leaving investors focused on whether those added costs will offset the deal’s long-term benefits.

Shares may also be facing added pressure from a recent analyst downgrade, which can amplify a negative reaction when new cost disclosures arrive ahead of earnings.

Sources:

SEC, Biogen, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BIIB Hedge Fund Activity

We have seen 465 institutional investors add shares of $BIIB stock to their portfolio, and 342 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 3,381,678 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $619,963,027
POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
BLACKROCK, INC. added 1,163,231 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $213,255,139
MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
WELLINGTON MANAGEMENT GROUP LLP removed 589,628 shares (-16.6%) from their portfolio in Q1 2026, for an estimated $108,096,501
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 521,385 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $95,585,512

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/05, 01/30 and 0 sales.
REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 06/29/2026
Evercore ISI Group issued a "Outperform" rating on 05/15/2026
Guggenheim issued a "Buy" rating on 04/30/2026
Oppenheimer issued a "Outperform" rating on 01/30/2026

To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.

Here are some recent targets:

Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
Matthew Harrison from Morgan Stanley set a target price of $224.0 on 06/18/2026
Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
Brian Abrahams from RBC Capital set a target price of $227.0 on 05/27/2026
David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.